Abstract

Alphatec Holdings will report quarterly results on May 5, 2026, Post Market; consensus points to double‑digit top-line growth and improved per‑share earnings versus last year, with investors focused on revenue execution, gross‑margin sustainability, and the trajectory toward profitability.

Market Forecast

Based on the latest compiled estimates, Alphatec Holdings is projected to deliver approximately 197.35 million US dollars in revenue for the current quarter, representing about 17.35% year‑over‑year growth. Adjusted EPS is modeled at around -$0.02, reflecting an approximate 90.30% year‑over‑year improvement, and EBIT is forecast at about 3.49 million US dollars, up roughly 113.30% year‑over‑year; margin forecasts have not been explicitly quantified in the collected dataset.

The main business is expected to maintain double‑digit growth supported by ongoing account additions and higher utilization, with management focus likely to remain on sustaining mix and efficiency gains into mid‑year. Within the portfolio, the U.S. commercial franchise continues to be identified as the pivotal growth vector; recent period revenue attributed to this business was 764.16 million US dollars, and company outlook commentary implies growth broadly aligned with the anticipated low‑to‑high‑teens expansion at the consolidated level.

Last Quarter Review

In the previous quarter, Alphatec Holdings reported revenue of 212.93 million US dollars, a gross profit margin of 70.21%, a GAAP net loss attributable to shareholders of 21.73 million US dollars, a net profit margin of -10.20%, and adjusted EPS of $0.06; revenue increased by approximately 20.44% year‑over‑year. A key highlight was profitability progression on an operating basis, with EBIT reaching 17.98 million US dollars, significantly above internal and external benchmarks, alongside a modest revenue beat of about 1.55 million US dollars versus consensus. Main business momentum was underpinned by higher case volumes and favorable mix, consistent with the 20.44% year‑over‑year revenue expansion and a 70.21% gross margin level that underscores pricing discipline and scale benefits.

Current Quarter Outlook

Main business performance and near-term execution

The base case for the current quarter centers on continued double‑digit growth, with revenue modeled at 197.35 million US dollars and year‑over‑year expansion of about 17.35%. Execution hinges on maintaining case‑volume momentum and protecting realized pricing as product mix evolves; these dynamics mattered last quarter and remain critical to sustaining the 70%‑range gross‑margin profile achieved previously. Operating leverage is another focal point: with EBIT forecast around 3.49 million US dollars, the company needs disciplined expense management to convert top‑line growth into incremental operating income despite ongoing commercial and R&D investments.

Several elements can lift or pressure results. A continuation of mix improvements supports gross margin, while the pace of new account activation and surgeon utilization influences run‑rate revenue. On the expense side, a normalized cadence of selling and clinical support costs can help preserve the estimated path toward breakeven on a per‑share basis; the model implies adjusted EPS improving to approximately -$0.02. Variability around procedure timing and hospital workflows may introduce short‑term noise, so attention will be on management’s intra‑quarter commentary about demand trends and any signs of order or scheduling deferrals.

Most promising growth vector within the portfolio

The U.S. commercial franchise remains the clearest internal growth vector highlighted in the collected data, with revenue for the most recent period of 764.16 million US dollars and an outlook tied to broadening utilization. Expansion of higher‑value procedural mixes can escalate revenue per case and support gross‑margin stability, which, in turn, improves the pathway to operating profitability. Product adoption curves and account penetration are likely to influence the pace of quarterly growth; incremental gains here should translate into above‑company‑average growth where complex procedure demand stays resilient.

From a profitability lens, this growth vector matters because it typically captures the benefits of solution breadth and integrated workflows, which can limit pricing pressure and support contribution margins. The near‑term watch item is whether the scaled revenue base can continue to offset elevated spending on sales infrastructure and innovation without diluting the gross‑margin baseline. If the franchise sustains momentum in line with the company’s low‑to‑high‑teens revenue expansion framework, the contribution to EBIT should be visible in the second‑half run rate.

Key stock-price swing factors this quarter

Gross‑margin commentary versus last quarter’s 70.21% result is a primary swing factor for the equity narrative. Investors are tracking whether mix and cost controls can keep margins near that level while revenue steps down sequentially from the holiday‑affected period. The degree of operating‑expense growth needed to support commercial efforts is the second swing factor; EBIT is modeled to compress sequentially to about 3.49 million US dollars, and any sign of tighter expense discipline could improve the EPS trajectory relative to the -$0.02 estimate.

Guidance and qualitative commentary will also matter. An updated view on full‑year revenue cadence, surgeon utilization trends into summer, and the shape of operating leverage in the back half can reset expectations. Finally, cash usage and any balance‑sheet signals are in focus given the path toward sustained profitability; if cash burn moderates and operating income begins to scale, the equity case for multiple stabilization strengthens. Conversely, if opex runs higher than anticipated or gross margin drifts from the 70% baseline, the path to the forecasted year‑over‑year EPS improvement becomes more challenging.

Analyst Opinions

Across the collected views from the last six months, opinions are decisively bullish. In our sample, Buy‑rated perspectives accounted for all tracked reports, resulting in a bullish‑to‑bearish ratio of 100% to 0%. Notable institutions include Barclays (Buy; price target cited at 27.00 US dollars), Stifel Nicolaus (Buy; recent targets referenced at 20.00 and 24.00 US dollars in separate updates), Needham (Buy; target lifted to 25.00 US dollars during the period), TD Cowen (Buy; 27.00 US dollars target), H.C. Wainwright (Buy; 24.00 US dollars target), and Lake Street (Buy; 25.00 US dollars target). The shared thesis emphasizes continued double‑digit revenue growth, sustained gross‑margin execution near recent levels, and a visible path toward operating profitability.

Analysts point to the company’s ability to translate case‑volume growth into top‑line expansion while defending gross-margin performance as central to near‑term upside. The prior quarter’s operating beat—EBIT of 17.98 million US dollars versus a materially lower expectation—has been cited by bulls as evidence that scale benefits are emerging. For the current quarter, the majority view expects revenue near 197.35 million US dollars and adjusted EPS around -$0.02, highlighting progress toward breakeven on a year‑over‑year basis. Commentary also stresses that incremental contributions from higher‑value mixes could support gross margin, while careful spending discipline may allow EBIT to stabilize despite sequential normalization from peak seasonal conditions.

On balance, the bullish consensus reflects confidence that the company can deliver the modeled 17.35% year‑over‑year revenue growth and maintain a constructive margin framework. The key inflection to watch is whether management reiterates or tightens its operating leverage narrative for the second half, signaling that last quarter’s profitability performance was not an outlier. With price targets clustered around the mid‑20s in US dollars, coverage implies upside anchored in consistent execution against revenue and margin milestones, though near‑term share reactions will remain sensitive to any deviations from the forecasted path, particularly around gross margin and expense cadence.